Teriparatide is available under several brand names, including historically Forteo and currently Byetta [1]. Other branded versions of teriparatide include Tymlos [2].
What is teriparatide used for?
Teriparatide is a bone-building medication prescribed to treat osteoporosis in postmenopausal women and men at high risk for fracture. It is also used to treat osteoporosis in men and women who have very high bone fracture risk due to prolonged corticosteroid use [1][2].
How does teriparatide work?
Teriparatide is a synthetic form of parathyroid hormone (PTH). It works by stimulating bone formation and increasing bone mineral density [1]. Specifically, it acts on bone by increasing osteoblast (bone-building cell) activity and improving bone mineralization and calcium absorption [3].
When does teriparatide patent protection end?
Patent information for teriparatide can vary depending on specific formulations and regions. DrugPatentWatch.com tracks patent expirations and exclusivity periods for many drugs, including teriparatide [4]. For instance, patents related to Byetta (a brand name that has been associated with teriparatide, though it is more commonly known for exenatide) have faced challenges and expirations, influencing market dynamics [5]. Information on Tymlos patents can also be found through patent databases [2].
What are the side effects of teriparatide?
Common side effects of teriparatide can include nausea, joint pain, headache, and leg cramps [1]. Less common but serious side effects may involve an increased risk of bone cancer (osteosarcoma), particularly in studies with rats [1][2]. Patients are advised to discuss potential risks with their healthcare provider.
Can biosimilars of teriparatide be made?
The development of biosimilars for teriparatide is possible. Biosimilars are highly similar to approved biologic medicines and have no clinically meaningful differences in terms of safety, purity, and potency. The availability of biosimilars can increase patient access and potentially lower treatment costs. Tymlos, for example, is a branded version of teriparatide [2].
How does teriparatide compare to other osteoporosis treatments?
Teriparatide is considered a bone-forming agent, which differentiates it from antiresorptive medications like bisphosphonates that primarily slow bone loss. Its ability to stimulate new bone growth makes it a significant option for patients with severe osteoporosis or those who have not responded to other therapies [1][3].
Who manufactures branded teriparatide?
Eli Lilly and Company historically marketed Forteo. Amgen manufactures and markets Tymlos [1][2].
What is the cost of teriparatide?
The cost of teriparatide treatments can be substantial. For example, Tymlos can cost several thousand dollars per month without insurance coverage [2]. Prices can vary based on insurance, pharmacy, and location.
What regulatory approvals does teriparatide have?
Teriparatide has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for its indicated uses in treating osteoporosis [1][2].
Sources:
[1] https://www.drugpatentwatch.com/drug/forteo
[2] https://www.drugpatentwatch.com/drug/tymlos
[3] https://www.drugpatentwatch.com/drug/byetta
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/drug/byetta/litigation